Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)
Program participation enables FDA discussions about the underlying platform, rather than only individual drug products.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rani Therapeutics (Nasdaq: RANI) announced acceptance of its RaniPill Capsule platform into the U.S. FDA’s Emerging Technology Program for early regulatory engagement.
Participation provides direct access to the FDA’s Emerging Technology Team to address technical and regulatory considerations through pre-submission meetings and potential site visits. Discussions can cover the underlying technology’s broader applicability rather than only individual drug products. Rani expects this engagement to support its work to automate its vertically integrated manufacturing process in anticipation of broader clinical use.
Positive
- Minor pointRaniPill acceptance into FDA’s Emerging Technology Program provides early, direct engagement on technical and regulatory considerations.
- Minor point. Forward-looking: it has not happened yet and may not happen.Platform-wide FDA discussions can address broader technology applicability beyond individual drug products.
- Minor point. Forward-looking: it has not happened yet and may not happen.Manufacturing automation is underway in anticipation of broader clinical use; Rani expects FDA engagement to be valuable.
Negative
- None.
Details
Market move: RANI -3.22% vs previous close. FDA program acceptance
On Oct 5, the day this news came out, the latest delayed price for RANI is 3.22% below the previous close. Our momentum scanner has recorded 2 alerts for this stock so far that day. The latest delayed price is $0.78.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Historical Context
-
Phase 1a RT-114 data reported RaniPill oral bioavailability above 150% versus matched subcutaneous dosing.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
biologics medical
cder regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
~ Acceptance into ETP enables early FDA engagement to support development of the RaniPill® platform technology ~
SAN JOSE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the RaniPill® Capsule™ platform technology has been accepted into the U.S. Food and Drug Administration (FDA) Emerging Technology Program (ETP).
The FDA’s Emerging Technology Program, administered within the Agency’s Center for Drug Evaluation and Research (CDER), is designed to support the development and implementation of innovative approaches to pharmaceutical product design and manufacturing. Technologies accepted into the program must demonstrate the potential to improve pharmaceutical product quality and incorporate novel elements for which the FDA has limited review or inspection experience. Participation provides Rani with early, direct engagement with the FDA’s Emerging Technology Team to address technical and regulatory considerations related to the RaniPill platform, including through pre-submission meetings and potential site visits. Importantly, these interactions can address the broader applicability of the underlying technology rather than being limited to individual drug products.
“Our acceptance into the FDA's Emerging Technology Program reflects the Agency's recognition of the RaniPill® platform as a novel and innovative approach to the oral delivery of biologics,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “This program enables direct, collaborative access to the FDA on a technology as novel as Rani’s, and we expect that engagement to be especially valuable as we work to automate our vertically integrated manufacturing process in anticipation of broader clinical use. Combined with our rare disease, immunology, and obesity focused partnerships with Chugai, ProGen and PegBio, this milestone reflects our continued confidence in the RaniPill platform's potential as an alternative to injectable biologics. We look forward to working closely with the FDA as we continue to advance the platform.”
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® Capsule™, a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® Capsule technology.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding the potential of Rani’s RaniPill® platform to convert injectable biologics into oral therapies, and to address unmet needs in the treatment of patients requiring injectable biologics, the anticipated value of Rani’s engagement with the FDA under the Emerging Technology Program, Rani’s plans to automate its vertically integrated manufacturing process in anticipation of broader clinical use, Rani’s expectations regarding its partnerships with Chugai, ProGen and PegBio and the continued development of the RaniPill platform. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “continue,” “intend,” “look forward to,” “potential,” “expect,” “will,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Rani’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Rani’s business in general and the other risks described in Rani’s filings with the Securities and Exchange Commission, including Rani’s annual report on Form 10-K for the year ended December 31, 2025, and subsequent filings and reports by Rani. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Rani undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Investor Contact:
investors@ranitherapeutics.com
Media Contact:
media@ranitherapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does FDA Emerging Technology Program acceptance mean for Rani Therapeutics’ RaniPill platform?
Acceptance gives Rani early, direct engagement with the FDA’s Emerging Technology Team on technical and regulatory considerations. Participation includes pre-submission meetings and potential site visits, with discussions able to address the underlying platform rather than only individual drug products.
What technologies qualify for the FDA Emerging Technology Program that accepted RaniPill?
Accepted technologies must demonstrate potential to improve pharmaceutical product quality and include novel elements for which the FDA has limited review or inspection experience. The program operates within the FDA’s Center for Drug Evaluation and Research and supports new approaches to pharmaceutical product design and manufacturing.